Evidence from a large, five-year international trial shows that adjuvant tamoxifen reduces the risk of breast cancer in high-risk women, but questions remain as to whether the benefits outweigh the risks.
“Further long-term follow-up to study breast-cancer incidence and mortality, other causes of death, and side effects in the current trials remains essential,” declares Dr. Jan Cuzick, director of the International Breast Cancer Intervention Study (IBIS-I), at the Trials Center, Cancer UK, London, England. The next trial by the investigators, IBIS-II, will consider using an aromatase inhibitor as an option.
The IBIS-1 trial is a double-blind, placebo-controlled, randomised study of tamoxifen, 20 mg/day for five years, in 7,144 women between the ages of 35 and 70 years, who were at increased risk of breast cancer. It is being carried out by clinicians in Britain and other European countries, Australia and New Zealand.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!